Eurobio Scientific SA
PAR:ALERS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.8
25.95
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALERS stock under the Base Case scenario is 15.47 EUR. Compared to the current market price of 25.75 EUR, Eurobio Scientific SA is Overvalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eurobio Scientific SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALERS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Eurobio Scientific SA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eurobio Scientific SA
Balance Sheet Decomposition
Eurobio Scientific SA
Current Assets | 143.9m |
Cash & Short-Term Investments | 89m |
Receivables | 31.6m |
Other Current Assets | 23.3m |
Non-Current Assets | 172.4m |
PP&E | 12.3m |
Intangibles | 153.1m |
Other Non-Current Assets | 7m |
Current Liabilities | 52.9m |
Accounts Payable | 13m |
Accrued Liabilities | 6.1m |
Other Current Liabilities | 33.8m |
Non-Current Liabilities | 88.4m |
Long-Term Debt | 86.2m |
Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
Eurobio Scientific SA
Revenue
|
144.2m
EUR
|
Cost of Revenue
|
-76.7m
EUR
|
Gross Profit
|
67.5m
EUR
|
Operating Expenses
|
-53.8m
EUR
|
Operating Income
|
13.7m
EUR
|
Other Expenses
|
-7.1m
EUR
|
Net Income
|
6.6m
EUR
|
Free Cash Flow Analysis
Eurobio Scientific SA
EUR | |
Free Cash Flow | EUR |
ALERS Profitability Score
Profitability Due Diligence
Eurobio Scientific SA's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Eurobio Scientific SA's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
ALERS Solvency Score
Solvency Due Diligence
Eurobio Scientific SA's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Eurobio Scientific SA's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALERS Price Targets Summary
Eurobio Scientific SA
According to Wall Street analysts, the average 1-year price target for ALERS is 30.6 EUR with a low forecast of 30.3 EUR and a high forecast of 31.5 EUR.
Dividends
Current shareholder yield for ALERS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALERS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
Contact
IPO
Employees
Officers
The intrinsic value of one ALERS stock under the Base Case scenario is 15.47 EUR.
Compared to the current market price of 25.75 EUR, Eurobio Scientific SA is Overvalued by 40%.